

PRESS RELEASE

Hansa Biopharma to participate in 26th Annual Biotech in Europe Forum

Lund, Sweden, October 2, 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in the State of the Industry Panel at the 26th Annual Biotech in Europe Forum, on Wednesday 7 October, at 8:30 CEST, at the Mövenpick Hotel Basel, Switzerland.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: State of the Industry Panel at the 26th Annual Biotech in Europe Forum

Date, Time and Place: Wednesday 7 October, 8:30 CEST, Mövenpick Hotel Basel, Switzerland

Co-chaired by:

- Hannah England, Partner, Ropes & Gray LLP
- Kelly Curtin, Managing Director, Stifel

Panellists:

- Renée Aguiar-Lucander, CEO, Hansa Biopharma AB
- Allan Marchington, Managing Director, Head of Life Sciences, Intermediate Capital Group PLC
- Chandra Leo, Investment Advisor, HBM Partners AG
- Nigel Layton, Global Head of Life Sciences, Forvis Mazars
- Sam Fazeli, Head of Research, Global Industries & Senior Pharmaceuticals Analyst, Bloomberg Intelligence

--- ENDS ---

Contacts for more information:

Adam Cutler, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on [LinkedIn](#).

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, Idefirix®, and Idefirix flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.